

8e Initia
Hoechst Celanese

8EHQ-1093-12725

Department of
Environmental, Health &
Safety Affairs (DEHSA)

A

October 4, 1993
MRS-131-93

Hoechst Celanese Corporation
Route 202-206
PO Box 2500
Somerville, NJ 08876-1258
908 231 2000
Telex 833 449
Fax 908 231 4554



8EHQ-93-12725
INIT 10/14/93



88940000011

Document Processing Center (TS-790)
U.S. Environmental Protection Agency
401 M Street, S.W.
Washington, D.C. 20460
Attn: TSCA Section 8(e) Coordinator

Dear Sir or Madam:

In accordance with the requirements of TSCA Section 8(e), Hoechst Celanese hereby submits a draft report for an acute oral toxicity study in rats of 4-(2-methoxyethyl)-phenol (CAS No. 56718-71-9). Although no animals died at the 1000 mg/kg dose of the chemical, effects on the central nervous system, manifested as narcosis, were observed in the rats.

The chemical in this study is a R&D chemical.

This submission contains no confidential business information.

If any further information is required, do not hesitate to contact Dr. Michele R. Sullivan, Director, Product Stewardship at 908-231-4480.

Sincerely,

Susan Engelman
Vice President, Environmental, Health & Safety Affairs


Encl.

CERTIFIED MAIL/
RETURN RECEIPT REQUESTED



File: Log No. 165

OCT 14 1993 8:25



Hoechst

C - 1565

[4-(2-Methoxyethyl)-phenol; CAS-No. 56718-71-9]

Testing for acute oral toxicity

in the male and female Wistar rat

DRAFT

Author

Dr. Hofmann

Draft report from 18.08.1993

Report completion date

Performing Laboratory

Pharma Development Central Toxicology
Hoechst Aktiengesellschaft
65926 Frankfurt am Main

Laboratory Project ID: Study No.

93.0253

This report contains the unpublished research findings of Hoechst scientists. It should not be published, in whole or in part, or referred to in any publication without authorization from the company.

DRAFT

STATEMENT OF COMPLIANCE

To the best of my knowledge and belief, this study was conducted in compliance with Good Laboratory Practice regulations. No unforeseen circumstances were observed which might have affected the quality or integrity of the study.

Study Director

(Dr. Hofmann)

Testing facility
Management

(Dr. Jung)

DRAFT

QUALITY ASSURANCE STATEMENT

Hoechst Aktiengesellschaft
Pharma Research
Quality Assurance (GLP)

DRAFT

CONTENTS

QUALITY ASSURANCE STATEMENT.....	4
1. SUMMARY.....	6
2. OBJECTIVE / GUIDELINE.....	7
3. SYNOPSIS.....	8
4. MATERIALS AND METHODS.....	9
4.1. Test substance.....	9
4.2. Test species and animal husbandry.....	10
4.3. Test groups.....	11
4.4. Preparation of the test substance.....	11
4.5. Test procedure.....	11
4.6. Statistics.....	11
5. RESULTS.....	12
5.1. Lethality.....	12
5.2. Clinical signs.....	13
5.3. Autopsy findings.....	13
6. APPENDIX.....	14
Dose range finding study.....	14
Body weight development and lethality - individual data....	15
Clinical signs and autopsy findings - individual data.....	21
Autopsy findings - individual data.....	39
Statistics (LD50 calculation).....	41

1. SUMMARY

The acute oral toxicity testing of C-1565 in the Wistar rat yielded the following median lethal dose (LD50):

Male and female animals	: 1933 mg/kg body weight
Male animals	: 1794 mg/kg body weight
Female animals	: 2082 mg/kg body weight

Lethality occurred at day one of the study. Beside unspecific symptoms the animals showed impairments of respiration, motility, reflexes and consciousness as well as prone position. Additionally one male animal of 1000 mg/kg body weight group and one female animal of the 2000 mg/kg body weight group showed respiratory sounds. Closed palpebral fissures were observed in one male animal of the 2500 mg/kg body weight group. One female of this dose group showed lacrimation. All animals were free of symptoms at day 8 of the study.

Development of body weight was not impaired.

Necropsy of the animals found dead revealed petechial bleedings in the stomach, diffuse reddening of stomach and intestinal mucosa as well as dark discolourations of the liver.

The animals killed at the end of the observation period were free of macroscopically visible changes.

2. OBJECTIVE / GUIDELINE

Testing for acute oral toxicity is an initial step in identifying the toxicological properties of a substance. It provides information on health risks resulting from a single oral intake and serves as a basis for classification. It permits the selection of optimum dose levels for repeated administration of the test substance. The Wistar rat has proved to be a suitable species for acute oral toxicity testing with many different substances.

The present study was conducted in compliance with

**OECD Guidelines for Testing of Chemicals, 401
"Acute Oral Toxicity", OECD 1987
Updated Guideline, adopted: 24 February 1987**

and

**EEC Guideline B.1, Acute Oral Toxicity
in Council Directive 84/449/EEC:
Commission Directive of 25 April 1984
adapting to technical progress for the sixth time
Council Directive 67/548/EEC on the approximation of the laws,
regulations and administrative provisions relating to the
classification, packaging and labelling of dangerous substances**

This study was conducted in compliance with the

**Principles of Good Laboratory Practice
Annex of paragraph 19a, section 1 of the chemical law
from August 1990**

3. SYNOPSIS

Type of study : acute oral toxicity
Study No. : 93.0253
Artemis No. : AR0718
Test substance : C-1565
Test species / sex : Wistar rat / male and female
Sponsor : Hoechst Celanese Technical Center
Start of study : June 23rd, 1993
End of study : August 11th, 1993
Dose level : 1000, 2000 and 2500 mg/kg body weight

R e s p o n s i b i l i t i e s

Testing Facility Management : Dr. Jung
Study Director : Dr. Hofmann
Analytics : Dr. Pletsch
Quality Assurance (GLP) : Ap. Harston (Pharmacist)

Testing Facility and Archive: Pharma Development Central Toxicology
HOECHST AKTIENGESELLSCHAFT
65926 Frankfurt am Main

All raw data obtained in the course of the study are stored in accordance with the SOP.

4. MATERIALS AND METHODS

4.1. Test substance

Code : 1565
Name : 4-(2-Methoxyethyl)phenol
Synonyms : MEP
CAS No. : 56718-71-9
Molecular formula : C₉H₁₂O₃
Appearance : clear to light yellow liquid
Molecular weight : 152 g/mol
Specific gravity : 1.06332 kg/l
Purity : 98.6 %
Batch Number : 50080-03
Identity : by NMR and infrared spectrum
Sample received on : May 13th, 1993
Storage conditions : darkness at room temperature in a fume cupboard
Storage stability : stable at least until April 30th, 1995
Stability and homogeneity of the test compound in the vehicle : is guaranteed for 4 hours

4.2. Test species and animal husbandry

Test species : Wistar rat
Strain : Hoe: WISKf(SPF71)
Source : HOECHST AG, Kastengrund, SPF breeding colony

Body Weight at start of study

males :	$\bar{x} = 176 \text{ g } (= 100 \%)$
	$s = \pm 8 \text{ g}$
	$x_{\min} = 157 \text{ g } (- 11.9 \%)$
	$x_{\max} = 182 \text{ g } (+ 3.4 \%)$
	$n = 15$

females :	$\bar{x} = 172 \text{ g } (= 100 \%)$
	$s = \pm 7 \text{ g}$
	$x_{\min} = 158 \text{ g } (- 8.1 \%)$
	$x_{\max} = 183 \text{ g } (+ 6.4 \%)$
	$n = 15$

Age at start of study

males :	approx. 7 weeks
females :	approx. 8 weeks

Randomization : Randomization schemes 415/92, 416/92, 93.210
93.453, 93.454 and 93.455

Animal maintenance : in fully air-conditioned rooms in Makrolon cages (Type 4) on soft wood granulate in groups of 5 animals

Room temperature : $22 \pm 3 \text{ }^{\circ}\text{C}$

Relative humidity : $55 \pm 20 \%$

Lighting time : 12 hours daily

Acclimatization : not necessary (breeding at identical conditions)

Withdrawal of food : from about 16 hours before to 3 - 4 hours after treatment

Food : Altromin 1324 rat diet (Altromin GmbH, Lage/Lippe), ad libitum

Water : tap water in plastic bottles, ad libitum

Animal identification : fur-marking with KMnO₄ and cage numbering

4.3. Test groups

Based on a dose range finding study the following dose levels were tested:

Dose mg/kg b.w.	Concentration % (w/v)	Volume applied (ml/kg b.w.)	Number of males / females	
1000	10	10	5	5
2000	20	10	5	5
2500	25	10	5	5

4.4. Preparation of the test substance

C-1565 was suspended in the stated concentrations in sesame oil (Oleum sesami Ph.Eur.III, from Mainland Pharmazeutische Fabrik GmbH, Frankfurt) and distributed homogeneously by means of a magnetic stirrer.

Stability and homogeneity of the test substance was determined by analytical methods.

4.5. Test procedure

The prepared test substance was administered by gavage to fasted animals at the stated dosage. The observation period following treatment lasted for 14 days. Symptoms and lethality were recorded twice every day (in the morning and in the afternoon), on weekends and holidays only once. Animals found dead were dissected as soon as possible and examined for macroscopically visible changes. During this time the animals were weighed weekly. At the end of the observation period surviving animals were killed by carbon dioxide asphyxiation, dissected and also examined for macroscopically visible changes.

4.6. Statistics

The LD₅₀, the 95 % limits of confidence and the equation of the probit-line were established on the basis of the lethality rates by probit analysis.

(method of FIELLER and SIDAK, programs supplied by Pharma Research and Development Informatics, HOECHST AG).

LD₅₀ values were calculated separately for male and female animals.

A common LD₅₀ based on the lethality rates of the male and female animals can be calculated if the 95 % confidence limit of the coefficient (relative efficacy) of both LD₅₀ values based on the comparison of both probit-lines includes the value 1.

(method of FIELLER and SIDAK, programs supplied by Pharma Research and Development Informatics, HOECHST AG).

5. RESULTS

5.1. Lethality

Under the conditions described above, the following lethality rates were observed:

Dose mg/kg b.w.	male animals		female animals	
	absolute	relative (%)	absolute	relative (%)
1000	0 / 5	0	0 / 5	0
2000	4 / 5	80	2 / 5	40
2500	4 / 5	80	4 / 5	80
LD50 (mg/kg b.w.)	1794		2082	
Confidence interval (P = 0.05)	519 - 2418		1010 - 3050	
common LD50 (mg/kg b.w.)	1933			
Confidence interval (P = 0.05)	1225 - 2282			

(for individual data, statistics and graph of the probit-line, see APPENDIX)

5.2. Clinical signs

The following clinical signs were observed after the application of C-1565 in males and females: decreased spontaneous activity, sunken flanks, squatting posture, prone position, bristling coat, stilted gait, uncoordinated or ataxic gait, forward crawling, panting, irregular respiration, decreased respiration rate, stupor, narcosis as well as absent placing reaction and absent pawreflex to pinching. Additionally, males and females of the 2000 and 2500 mg/kg body weight group showed absent corneal reflex. Respiratory sounds occurred in one male animal of the 1000 mg/kg body weight group and one female animal of the 2000 mg/kg body weight group. Closed palpebral fissures and reduced pawreflex to pinching were observed in one male animal of the 2500 mg/kg body weight group. One female of this dose group showed lacrimation. All animals were free of symptoms at day 8 of the study.

Development of body weight was not impaired.

(For individual data on clinical signs and development of body weight, see APPENDIX)

5.3. Autopsy findings

Macroscopic examination of the animals found dead revealed the following findings:

- | | |
|------------------|-------------------------------|
| Liver: | - dark discolouration |
| Stomach: | - petechial bleedings |
| | - diffuse reddening of mucosa |
| Small intestine: | - diffuse reddening of mucosa |

The animals killed at the end of the observation period showed no macroscopically visible changes.

(For individual autopsy findings, see APPENDIX)

Dr. TH/GL

Quality Assurance (GLP)

HOECHST AKTIENGESELLSCHAFT
Pharma Development Central Toxicology

Dr. Hofmann
Study Director

Dr. Jung
Industrial Toxicology

6. APPENDIX

Dose range finding study


Test substance : C-1565
Vehicle : sesame oil
Concentrations : 20 % (2000 mg/kg body weight)
5 % (500 mg/kg body weight)
Test species / sex : Wistar rat / male and female

Dose mg/kg b.w.	sex (m/f)	Appl. date time	body weight days after start study g	lethality	
				time p.a.	b.w. g
2000	m	23.06.93 7.25	154	115' 115'	
	f		160		
500	m	24.06.93 8.15	157 162	227 200	285 217
	f				


Comprehensive description of clinical signs: Beside unspecific symptoms the animals showed impairments of respiration, motility and reflexes. Additionally, stupor, prone position and narcosis were observed.

Comprehensive description of macroscopic findings: The mucosa of the small intestine showed diffuse reddening in the animals found dead.

The animals killed at the end of the observation period showed no macroscopically visible changes.



LAC910-09/03 LAC910P/2 HOECHST AKTIENGESELLSCHAFT INDUSTRIE
SECTION: PHARMA DEV. CENTRAL TOXICOLOGY RUN DATE: 16/08/93 PAGE: 2



(D) - ANIMAL DEAD

		INDIVIDUAL BODY WEIGHT DATA (g)										SECTION: PHARMA DEV. CENTRAL TOXICOLOGY		PAGE: 3		
		STUDY NO.: AR0718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION														
GROUP: 3		COMPOUND: H00013/001										DOSE: 2500 mg/kg				
ANIMAL NUMBER		DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15
MALES																
21		171	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22		174 (D)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23		174 (D)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24		170 (D)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25		172 (D)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
MEAN S.D.		172.2	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FEMALES																
26		168	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27		174 (D)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
28		175 (D)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29		170 (D)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30		180 (D)	-	-	-	-	-	-	-	-	-	-	-	-	-	-
MEAN S.D.		173.4	-	-	-	-	-	-	-	-	-	-	-	-	-	-

(D) - ANIMAL DEAD

LAC912-09/03 LAC912P/2

HOECHST AKTIENGESELLSCHAFT

RUN DATE: 16/08/93

PAGE: 1

INDIVIDUAL BODY WEIGHT GAINS(g)

STUDY NO: AR0718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

GROUP:	1	COMPOUND :	H00013/001	DOSE: 1000 mg/kg	WEIGHT GAINS ARE BETWEEN DAY 1 AND THE DAYS PRINTED										
					DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11

MALES

1	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-

MEAN S.D.


45.6 8.5

FEMALES

6	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-

MEAN S.D.

46.2 4.1



LAC912-09/03 LAC912P/2

HOECHST AKTIENGESELLSCHAFT

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

INDIVIDUAL BODY WEIGHT GAINS(g)

PAGE: 2

STUDY NO.: A60718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

ANIMAL NUMBER	WEIGHT GAINS ARE BETWEEN DAY				DOSE: 2000 mg/kg			
	1	2	3	4	5	6	7	8
11	0 (D)	-	-	-	-	-	-	
12	0 (D)	-	-	-	-	-	-	
13	0 (D)	-	-	-	-	-	-	
14	0 (D)	-	-	-	-	-	-	
15	0 (D)	-	-	-	-	-	-	

MALES

MEAN S.D.

117.0

60.0

FEMALES

MEAN S.D.

42 (D)

34 (D)

38.3

4.0

RUN DATE: 16/08/93

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

INDIVIDUAL BODY WEIGHT GAINS(g)

PAGE: 2

STUDY NO.: A60718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

ANIMAL NUMBER	WEIGHT GAINS ARE BETWEEN DAY				DOSE: 2000 mg/kg			
	1	2	3	4	5	6	7	8
11	0 (D)	-	-	-	-	-	-	
12	0 (D)	-	-	-	-	-	-	
13	0 (D)	-	-	-	-	-	-	
14	0 (D)	-	-	-	-	-	-	
15	0 (D)	-	-	-	-	-	-	

MALES

MEAN S.D.

117 (D)

60.0

FEMALES

MEAN S.D.

39 (D)

34 (D)

38.3

4.0

LAC912-09/03 LAC912P/2

HOECHST AKTIENGESELLSCHAFT

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

INDIVIDUAL BODY WEIGHT GAINS(g)

STUDY NO: A0718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

PAGE: 3

RUN DATE: 16/08/93

GROUP: 3 COMPOUND : H00013/001
WEIGHT GAINS ARE BETWEEN DAY 1 AND THE DAYS PRINTED
DOSE: 2500 mg/kg

ANIMAL NUMBER	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	DAY 15	
MALES	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	0 (0)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	0 (0)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	0 (0)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	0 (0)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	0 (0)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

MEAN S.D.

FEMALES
MEAN S.D.

26 (D) 105.0

105.0

MEAN S.D.

RUN DATE: 16/08/93

HOECHST AKTIENGESELLSCHAFT

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

PAGE: 1

CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT

[RELATIVE TIME AFTER FIRST DOSE 1

COMPOUND NUMBER : H00013/001

STUDY NUMBER: A00718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

LAC700-02/01 LACTOPP/2

HOECHST AKTIENGESELLSCHAFT


SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

PAGE: 1

GROUP:	1	DOSE LEVEL:	1000	DOSE UNIT:	mg/kg	SEX: MALE
--------	---	-------------	------	------------	-------	-----------

DAY NUMBER	00 MI	10 MI	30 MI	60 MI	01 HR	02 HR	04 HR	08 HR
START TIME	10 MI				1	1	1	1
FINISH TIME	30 MI				02 MI	04 MI	08 MI	08 MI
NO. OF ANIMALS DOSED	5	5	5	5	5	5	5	5
NO. OF ANIMALS SURVIVED	5	5	5	5	5	5	5	5

PANTING
IRREGULAR RESPIRATION
STUPOR
COAT BRISTLING
FLANKS DRAWN IN
STILTED GAIT
ATACTIC GAIT
UNCOORDINATED GAIT
FORWARD CRAWLING
PRONE POSITION
SQUATTING POSTURE
NARCOSIS
NO PAREFLEX TO PINCHING
DECR. SPONTANEOUS ACTIVITY



LAC700-02/01 LACT00P/2

HOECHST AKTIENGESELLSCHAFT

RUN DATE: 16/08/93

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT
[ABSOLUTE TIME AFTER ANIMAL START DATE]

STUDY NUMBER: AR0718 TITLE: STUDY NO.: 93-0253 ORAL ADMINISTRATION

PAGE: 2

COMPOUND NUMBER : H00013/0001

GROUP: 1 DOSE LEVEL: 1000 DOSE UNIT: mg/kg SEX: MALE

DAY NUMBER	7	8	9	10	11	12	13	14	15
START TIME	07:00	07:00	07:00	07:00	07:00	07:00	07:00	07:00	07:00
FINISH TIME	16:00	16:00	16:00	16:00	16:00	16:00	16:00	16:00	16:00
NO. OF ANIMALS DOSED	5	5	5	5	5	5	5	5	5
NO. OF ANIMALS SURVIVED	5	5	5	5	5	5	5	5	5
NO ABNORMALITIES DETECTED	-	-	-	-	-	-	-	-	-
KILLED AT END OF STUDY	-	-	-	-	-	-	-	-	-
DISSECTION: NO MACR. FINDG.	-	-	-	-	-	-	-	-	-

Report No. 93.0586
Page 23 (42)

LACT700-02/01 LAC700P/2

HOECHST AKTIENGESELLSCHAFT

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT
[RELATIVE TIME AFTER FIRST DOSE]

PAGE: 2

COMPOUND NUMBER : H00013/001

STUDY NUMBER: AR0718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

GROUP: 2 DOSE LEVEL: 2000 DOSE UNIT: mg/kg SEX: MALE

DAY NUMBER	1	1	1	1	1	1	1	1
START TIME	00 MI	10 MI	30 MI	01 HR	02 HR	04 HR	08 HR	08 HR
FINISH TIME	10 MI	30 MI	60 MI	02 HR	04 HR	04 HR	04 HR	04 HR
NO. OF ANIMALS DOSED	5	5	5	5	5	5	5	5
NO. OF ANIMALS SURVIVED	5	5	5	5	5	5	5	5
DECREASED RESPIRAT RATE	-	3	3	3	1	-	-	-
PANTING	5	5	5	5	5	5	5	5
IRREGULAR RESPIRATION	4	-	-	-	-	-	-	-
STUPOR	-	-	-	-	-	-	-	-
FLANKS DRAWN IN	-	-	-	-	-	-	-	-
STILTED GAIT	-	-	-	-	-	-	-	-
UNCOORDINATED GAIT	-	-	-	-	-	-	-	-
FORWARD CRAWLING	1	-	-	-	-	-	-	-
PRONE POSITION	4	-	-	-	-	-	-	-
SQUATTING POSTURE	-	-	-	-	-	-	-	-
NARCOSIS	1	-	-	-	-	-	-	-
NO CORNEAL REFLEX	-	-	-	-	-	-	-	-
NO PALPREFLEX TO PINCHING	-	-	-	-	-	-	-	-
NO PLACING REACTION	2	-	-	-	-	-	-	-
DEC.R SPONTANEOUS ACTIVITY	-	-	-	-	-	-	-	-
DIED	-	-	-	-	-	-	-	-

RUN DATE: 16/08/93

Pharma Development
Central Toxicology

Report No. 93.0586
Page 24 (42)

LAC700-02/01 LAC700P/2

HOECHST AKTIENGESELLSCHAFT

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

PAGE: 3

CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT

[ABSOLUTE TIME AFTER ANIMAL START DATE]

COMPOUND NUMBER : H00013/001

STUDY NUMBER: AR0718

TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

GROUP: 2 DOSE LEVEL: 2000 DOSE UNIT: mg/kg SEX: MALE

DAY NUMBER	2	2	3	3	4	4	5	5	6	6
START TIME	07:00	12:00	07:00	12:00	07:00	12:00	07:00	12:00	07:00	12:00
FINISH TIME	12:00	16:00	12:00	16:00	12:00	16:00	12:00	16:00	12:00	16:00
NO. OF ANIMALS DOSED	5	5	5	5	5	5	5	5	5	5
NO. OF ANIMALS SURVIVED	1	1	1	1	1	1	1	1	1	1
NO ABNORMALITIES DETECTED	1	1	1	1	1	1	1	1	1	1
FLANKS DRAWN IN	-	-	-	-	-	-	-	-	-	-
STILTLED GAIT	-	-	-	-	-	-	-	-	-	-
SQUATTING POSTURE	-	-	-	-	-	-	-	-	-	-

RUN DATE: 16/08/93

CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT

[ABSOLUTE TIME AFTER ANIMAL START DATE]

PAGE: 3

COMPOUND NUMBER : H00013/001

STUDY NUMBER: AR0718

TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

GROUP: 2 DOSE LEVEL: 2000 DOSE UNIT: mg/kg SEX: MALE

DAY NUMBER	2	2	3	3	4	4	5	5	6	6
START TIME	07:00	12:00	07:00	12:00	07:00	12:00	07:00	12:00	07:00	12:00
FINISH TIME	12:00	16:00	12:00	16:00	12:00	16:00	12:00	16:00	12:00	16:00
NO. OF ANIMALS DOSED	5	5	5	5	5	5	5	5	5	5
NO. OF ANIMALS SURVIVED	1	1	1	1	1	1	1	1	1	1
NO ABNORMALITIES DETECTED	1	1	1	1	1	1	1	1	1	1
FLANKS DRAWN IN	-	-	-	-	-	-	-	-	-	-
STILTLED GAIT	-	-	-	-	-	-	-	-	-	-
SQUATTING POSTURE	-	-	-	-	-	-	-	-	-	-

Report No. 93.0586
Page 25 (42)

LAC700-02/01 LAC700P/2

HOECHST AKTIENGESELLSCHAFT

RUN DATE: 16/08/93

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT
[ABSOLUTE TIME AFTER ANIMAL START DATE]

PAGE: 4

STUDY NUMBER: ARO718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

COMPOUND NUMBER : H00013/001

GROUP: 2 DOSE LEVEL: 2000 DOSE UNIT: mg/kg SEX: MALE

DAY NUMBER	7	8	9	10	11	12	13	14	15
START TIME	07:00	07:00	07:00	07:00	07:00	07:00	07:00	07:00	07:00
FINISH TIME	16:00	16:00	16:00	16:00	16:00	16:00	16:00	16:00	16:00
NO. OF ANIMALS DOSED	5	5	5	5	5	5	5	5	5
NO. OF ANIMALS SURVIVED	1	1	1	1	1	1	1	1	1
NO. ABNORMALITIES DETECTED	1	1	1	1	1	1	1	1	1
KILLED AT END OF STUDY	-	-	-	-	-	-	-	-	-
DISSECTION: NO MGR. FINDG.	-	-	-	-	-	-	-	-	-

PAGE: 4

PRINT

TIME

TO

RESPONSE

CLINICAL

OBSERVATIONS

TIME

AFTER

ANIMAL

START

DATE

J

1

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

PPA

LAC700-02/01 LAC700P/2

HOECHST AKTIENGESELLSCHAFT

RUN DATE: 16/08/93

Pharma Development
Central Toxicology

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT
(RELATIVE TIME AFTER FIRST DOSE)

PAGE: 3

STUDY NUMBER: A0718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

COMPOUND NUMBER : H00013/001

GROUP: 3 DOSE LEVEL: 2500 DOSE UNIT: mg/kg SEX: MALE

DAY NUMBER	1	1	1	1	1	1	1
START TIME	00 MI	10 MI	30 MI	01 HR	02 HR	04 HR	08 HR
FINISH TIME	10 MI	30 MI	60 MI	02 HR	04 HR	08 HR	
NO. OF ANIMALS DOSED	5	5	5	5	5	5	2
NO. OF ANIMALS SURVIVED	5	5	3	3	3	2	

NO ABNORMALITIES DETECTED
DECREASED RESPIR RATE
PANTING
IRREGULAR RESPIRATION
STUPOR
COAT BRISTLING
FLANKS DRAWN IN
STILTED GAIT
ATACTIC GAIT
UNCOORDINATED GAIT
FORWARD CRAWLING
PRONE POSITION
SQUATTING POSTURE
PALPEB. FISSURE CLOSED
NARCOSIS
NO CORNEAL REFLEX
RED. PAREL. TO PINCHING
NO PAWREFLEX TO PINCHING
NO PLACING REACTION
DEC.R. SPONTANEOUS ACTIVITY
DIED
FOUND DEAD

Report No. 93.0586
Page 27 (42)

LAC700-02/01 LAC700P/2
HOECHST AKTIENGESELLSCHAFT


SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT
[ABSOLUTE TIME AFTER ANIMAL START DATE]

STUDY NUMBER: AR0718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

PAGE: 5

GROUP:	3	DOSE LEVEL:	2500	DOSE UNIT:	mg/kg	SEX: MALE
DAY NUMBER				2	3	4
START TIME	07:00	12:00	12:00	07:00	12:00	07:00
FINISH TIME	12:00	16:00	16:00	12:00	16:00	12:00
NO. OF ANIMALS DOSED	5	5	5	5	5	5
NO. OF ANIMALS SURVIVED	1	1	1	1	1	1
NO. ABNORMALITIES DETECTED	1	1	1	1	1	1
IRREGULAR RESPIRATION						
FLANKS DRAWN IN						
STILTED GAIT						
UNCOORDINATED GAIT						
SQUATTING POSTURE						



LAC700-02/01 LAC700P/2

HOECHST AKTIENGESELLSCHAFT

RUN DATE: 16/03/93

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT
[ABSOLUTE TIME AFTER ANIMAL START DATE]

PAGE: 6

COMPOUND NUMBER : H00013/001

STUDY NUMBER: ARO718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

GROUP: 3 DOSE LEVEL: 2500 DOSE UNIT: mg/kg SEX: MALE

DAY NUMBER	7	8	9	10	11	12	13	14	15
START TIME	07:00	07:00	07:00	07:00	07:00	07:00	07:00	07:00	07:00
FINISH TIME	16:00	16:00	16:00	16:00	16:00	16:00	16:00	16:00	16:00
NO. OF ANIMALS DOSED	5	5	5	5	5	5	5	5	5
NO. OF ANIMALS SURVIVED	1	1	1	1	1	1	1	1	0
NO. ABNORMALITIES DETECTED	1	1	1	1	1	1	1	1	1
KILLED AT END OF STUDY	:	-	-	-	-	-	-	-	-
DISSECTION: NO MACR. FINDG.									

Report No. 93.0586
Page 29 (42)

RUN DATE: 16/08/93

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT
[RELATIVE TIME AFTER FIRST DOSE]

STUDY NUMBER: AR0718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

COMPOUND NUMBER : H00013/001

LAC700-02/01 LAC700P/2

HOECHST AKTIENGESELLSCHAFT

GROUP: 1

DOSE LEVEL:

1000

DOSE UNIT: mg/kg

SEX: FEMALE

DAY NUMBER	1	1	1	1	1	1	1	1
START TIME	00 MI	10 MI	30 MI	01 HR	02 HR	04 HR	08 HR	
FINISH TIME	10 MI	30 MI	60 MI	02 HR	04 HR	08 HR		
NO. OF ANIMALS DOSED	5	5	5	5	5	5	5	
NO. OF ANIMALS SURVIVED	5	5	5	5	5	5	5	
PANTING	1	2	2	1	1	1	1	
IRREGULAR RESPIRATION	3	3	3	2	2	2	2	
STUPOR	1	1	1	1	1	1	1	
COAT BRISTLING	-	-	-	-	-	-	-	
FLANKS DRAWN IN	-	-	-	-	-	-	-	
STILTED GAIT	2	2	2	2	2	2	2	
ATACTIC GAIT	3	2	1	3	2	2	2	
UNCOORDINATED GAIT	3	2	1	3	2	2	2	
FORWARD CRAWLING	-	-	-	-	-	-	-	
PRONE POSITION	-	-	-	-	-	-	-	
SQUATTING POSTURE	-	-	-	-	-	-	-	
NARCOSIS	-	-	-	-	-	-	-	
NO PAREFLEX TO PINCHING	-	-	-	-	-	-	-	
DECER. SPONTANEOUS ACTIVITY	3	2	2	2	2	2	2	

LAC700-02/01 LAC700P/2

HOECHST AKTIENGESELLSCHAFT

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

PAGE: 1

CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT
[ABSOLUTE TIME AFTER ANIMAL START DATE]

PAGE: 1

STUDY NUMBER: AR0718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

COMPOUND NUMBER : H00013/001

GROUP: 1 DOSE LEVEL: 1000 DOSE UNIT: mg/kg SEX: FEMALE

DAY NUMBER	2	3	4	5	6
START TIME	07:00	12:00	07:00	07:00	07:00
FINISH TIME	12:00	16:00	12:00	12:00	12:00
NO. OF ANIMALS DOSED	5	5	5	5	5
NO. OF ANIMALS SURVIVED	5	5	5	5	5
NO. ABNORMALITIES DETECTED	-	1	1	5	-
STILTED GAIT	5	5	4	1	-
UNCOORDINATED GAIT	3	3	1	1	-
SQUATTING POSTURE	4	4	2	2	-

LAC700-02/01 LAC700P/2
HOECHST AKTIENGESELLSCHAFT

C L I N I C A L O B S E R V A T I O N S T I M E T O R E S P O N S E P R I N T

PAGE: 2


PAGE:

COMPOUND NUMBER : H00013/001

STUDY NUMBER: AR0718 TITLE: STUDY NO.: 93-0253 ORAL ADMINISTRATION

GROUP: 1
DOSE LEVEL: 1000
DOSE UNIT: mg/kg
SEX: FEMALE

DAY NUMBER	7	8	9	10	11	12	13	14	15
START TIME	07:00	07:00	07:00	07:00	07:00	07:00	07:00	07:00	07:00
FINISH TIME	16:00	16:00	16:00	16:00	16:00	16:00	16:00	16:00	16:00
NO. OF ANIMALS DOSED	5	5	5	5	5	5	5	5	5
NO. OF ANIMALS SURVIVED	5	5	5	5	5	5	5	5	5
NO ABNORMALITIES DETECTED	-	-	-	-	-	-	-	-	-
KILLED AT END OF STUDY	-	-	-	-	-	-	-	-	-
DISSECTION: NO MACR. FINDG.	-	-	-	-	-	-	-	-	-



LAC700-02/01 LAC700P/2

HOECHST AKTIENGESELLSCHAFT

RUN DATE: 16/08/93

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT
[RELATIVE TIME AFTER FIRST DOSE]

STUDY NUMBER: AR0718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

PAGE: 2

COMPOUND NUMBER : H00013/001

GROUP:	2	DOSE LEVEL:	2000	DOSE UNIT:	mg/kg	SEX: FEMALE
DAY NUMBER				1	1	1
START TIME				00 MI	10 MI	30 MI
FINISH TIME				10 MI	30 MI	60 MI
NO. OF ANIMALS DOSED	5			5	5	5
NO. OF ANIMALS SURVIVED	5			5	5	5
DECREASED RESPIRAT.RATE	-			3	3	3
PANTING	-			5	5	5
IRREGULAR RESPIRATION	-			3	3	3
STUPOR	-			-	1	2
COAT BRISTLING	-			-	1	2
FLANKS DRAWN IN	-			-	1	2
STILTED GAIT	-			-	1	2
ATACTIC GAIT	-			-	1	2
FORWARD CRAWLING	-			-	1	2
PRONE POSITION	-			-	1	2
SQUATTING POSTURE	-			-	1	2
NARCOSIS	2			5	5	5
NO CORNEAL REFLEX	-			-	1	2
NO PAREFLEX TO PINCHING	-			-	1	2
NO PLACING REACTION	-			-	1	2
DEC.R.SPOONTANEOUS ACTIVITY	-			-	1	2
DIED	-			-	1	2

Report No. 93.0586
Page 33 (42)

RUN DATE: 16/08/93
SECTION: PHARMA DEV. CENTRAL TOXICOLOGY
CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT
[ABSOLUTE TIME AFTER ANIMAL START DATE]
PAGE: 3
COMPOUND NUMBER : H00013/001

STUDY NUMBER: ARO718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

GROUP: 2 DOSE LEVEL: 2000 DOSE UNIT: mg/kg SEX: FEMALE

DAY NUMBER	2	2	3	4	5	6
START TIME	07:00	12:00	07:00	12:00	07:00	12:00
FINISH TIME	12:00	16:00	12:00	16:00	12:00	16:00
NO. OF ANIMALS DOSED	5	5	5	5	5	5
NO. OF ANIMALS SURVIVED	3	3	3	3	3	3
RESPIRATORY SOUNDS	-	-	-	-	1	1
IRREGULAR RESPIRATION	3	3	3	-	-	-
FLANKS DRAINED	3	3	3	-	-	-
STILTED GAIT	3	3	3	-	-	-
UNCOORDINATED GAIT	1	1	2	-	3	3
SQUATTING POSTURE	3	3	3	-	2	2
DECRED. SPONTANEOUS ACTIVITY	2	2	-	-	-	-

LAC700-02/01 LACT00P/2
HOECHST AKTIENGESELLSCHAFT

CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT
[ABSOLUTE TIME AFTER ANIMAL START DATE]


STUDY NUMBER: AR0718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

PAGE: 4

COMPOUND NUMBER : H00013/001

GROUP: 2 DOSE LEVEL: 2000 DOSE UNIT: mg/kg SEX: FEMALE

DAY NUMBER	7	8	9	10	11	12	13	14	15
START TIME	07:00	07:00	07:00	07:00	07:00	07:00	07:00	07:00	07:00
FINISH TIME	16:00	16:00	16:00	16:00	16:00	16:00	16:00	16:00	16:00
NO. OF ANIMALS DOSED	5	5	5	5	5	5	5	5	5
NO. OF ANIMALS SURVIVED	3	3	3	3	3	3	3	3	3
NO ABNORMALITIES DETECTED	2	3	3	3	-	-	-	-	-
RESPIRATORY SOUNDS	1	-	-	-	-	-	-	-	-
KILLED AT END OF STUDY	-	-	-	-	-	-	-	-	-
DISSECTION: NO MACR. FINDG.	-	-	-	-	-	-	-	-	-



LAC700-02/01 LAC700P/2

HOECHST AKTIENGESELLSCHAFT

RUN DATE: 16/08/93

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT
[RELATIVE TIME AFTER FIRST DOSE]

STUDY NUMBER: ARO718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

PAGE: 3


COMPOUND NUMBER : H00013/001

GROUP:	3	DOSE LEVEL:	2500	DOSE UNIT:	mg/kg	SEX: FEMALE
DAY NUMBER				1	1	
START TIME				00 MI	10 MI	
FINISH TIME				10 MI	30 MI	
NO. OF ANIMALS DOSED				5	5	
NO. OF ANIMALS SURVIVED				5	2	
DECREASED RESPIRAT. RATE	-	-	-	3	2	1
PANTING	-	-	-	5	2	1
IRREGULAR RESPIRATION	-	-	-	-	-	1
STUPOR	-	-	-	-	-	1
ATACTIC GAIT	-	-	-	-	-	2
PRONE POSITION	-	-	-	-	-	2
NARCOSIS	-	-	-	-	-	2
NO CORNEAL REFLEX	-	-	-	-	-	2
NO PAREFLEX TO PINCHING	-	-	-	-	-	2
NO PLACING REACTION	-	-	-	-	-	2
DEC.R.SPOONTANEOUS ACTIVITY	-	-	-	-	-	1
DIED	-	-	-	-	-	3
LACRIMATION CLEAR,COLORL.	-	-	-	-	-	-

Report No. 93.0586
Page 36 (42)

RUN DATE: 16/08/93
SECTION: PHARMA DEV. CENTRAL TOXICOLOGY
CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT
[ABSOLUTE TIME AFTER ANIMAL START DATE]
PAGE: 5
STUDY NUMBER: ARO718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION
COMPOUND NUMBER : H00013/001

GROUP:	3	DOSE LEVEL:	2500	DOSE UNIT:	mg/kg	SEX:	FEMALE
DAY NUMBER	2		2		3		
START TIME	07:00	12:00	07:00	12:00	07:00	12:00	
FINISH TIME	12:00	16:00	12:00	16:00	12:00	16:00	
NO. OF ANIMALS DOSED	5	5	5	5	5	5	
NO. OF ANIMALS SURVIVED	1	1	1	1	1	1	
NO ABNORMALITIES DETECTED	-	-	-	-	-	-	
IRREGULAR RESPIRATION	1	1	1	1	1	1	
FLANKS DRAWN IN	1	1	1	1	1	1	
STILTED GAIT	1	1	1	1	1	1	
UNCOORDINATED GAIT	1	1	1	1	1	1	
SQUATTING POSTURE	1	1	1	1	1	1	
DEC.R. SPONTANEOUS ACTIVITY	1	1	1	1	1	1	



LAC700-02/01 LACT00P/2

HOECHST AKTIENGESELLSCHAFT

RUN DATE: 16/08/93

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

PAGE: 6

CLINICAL OBSERVATIONS TIME TO RESPONSE PRINT
[ABSOLUTE TIME AFTER ANIMAL START DATE]

PAGE:

STUDY NUMBER: ARO718 TITLE: STUDY NO.: 93.0253 ORAL ADMINISTRATION

COMPOUND NUMBER : H00013/001

GROUP: 3 DOSE LEVEL: 2500 DOSE UNIT: mg/kg SEX: FEMALE

DAY NUMBER	7	8	9	10	11	12	13
START TIME	07:00	07:00	07:00	07:00	07:00	07:00	07:00
FINISH TIME	16:00	16:00	16:00	16:00	16:00	16:00	16:00
NO. OF ANIMALS DOSED	5	5	5	5	5	5	5
NO. OF ANIMALS SURVIVED	1	1	1	1	1	1	1
NO ABNORMALITIES DETECTED KILLED AT END OF STUDY DISSECTION: NO MACR FINDG.	-	-	-	-	-	-	-

D
A
T
A
F
Y

RUN DATE: 16/08/93

PAC920-11/05 PAC920P/2
HOECHST AKTIENGESELLSCHAFT

SECTION: PHARMA DEV. CENTRAL TOXICOLOGY

PAGE: 1

PATHOLOGY - INTERGROUP COMPARISON OF MACROSCOPIC FINDINGS INCIDENCE
STUDY NO: ARO718 TITLE: STUDY NO.: 93.053 ORAL ADMINISTRATION

REMOVAL REASON: INTERCURRENT
SEX: MALES
MALES ON STUDY
ANIMALS COMPLETED

	GROUP 1 1000 mg/kg	GROUP 2 2000 mg/kg	GROUP 3 2500 mg/kg
LIVER NO. WITH FINDINGS BUT NOT SUBMITTED DARK DISCOLORATION.....	0	4	5
STOMACH NO. WITH FINDINGS BUT NOT SUBMITTED.....	0	4	4
STOMACH PETECHIAL BLEEDINGS.....	0	0	0
STOMACH DIFFUSE REDDING OF MUCOSA.....	0	0	0
SMALL INTESTINE NO. WITH FINDINGS BUT NOT SUBMITTED DIFFUSE REDDING.....	0	0	0


LIVER
NO. WITH FINDINGS BUT NOT SUBMITTED
DARK DISCOLORATION.....

STOMACH
NO. WITH FINDINGS BUT NOT SUBMITTED.....

STOMACH
PETECHIAL BLEEDINGS.....

STOMACH
DIFFUSE REDDING OF MUCOSA.....

SMALL INTESTINE
NO. WITH FINDINGS BUT NOT SUBMITTED
DIFFUSE REDDING.....



RUN DATE: 16/08/93


PAC920-11/05 PAC920P/2
HOECHST AKTIENGESELLSCHAFT

P A T H O L O G Y - I N T E R G R O U P C O M P A R I S O N O F M A C R O S C O P I C F I N D I N G S I N C I D E N C E
S T U D Y N O : A R 0 7 1 8 T I T L E : S T U D Y N O . : 9 3 - 0 2 5 3 O R A L A D M I N I S T R A T I O N

S E C T I O N : P H A R M A D E V . C E N T R A L T O X I C O L O G Y

P A G E : 2


R E M O V A L R E A S O N : I N T E R C U R R E N T	S E X : F E M A L E S	F E M A L E S O N S T U D Y		
		G R O U P 1 1 0 0 0 m g / k g	G R O U P 2 2 0 0 0 m g / k g	G R O U P 3 2 5 0 0 m g / k g
L I V E R	F E M A L E S A N I M A L S C O M P L E T E D	5	5	5
N O . W I T H F I N D I N G S B U T N O T S U B M I T T E D		0	2	4
D A R K D I S C O L O R A T I O N		0	2	4
S T O M A C H		0	0	0
N O . W I T H F I N D I N G S B U T N O T S U B M I T T E D		0	0	0
P E T E C H I A L , B L E E D I N G S		0	0	0
D I F F U S E R E D D E N I N G O F M U C O S A		0	0	0
S M A L L I N T E S T I N E		0	0	0
N O . W I T H F I N D I N G S B U T N O T S U B M I T T E D		0	0	0
D I F F U S E R E D D E N I N G		0	0	0



Program : ED 1.1
Substance : 4-(2-Methoxyethyl)-phenol
Species : rat

The Probit Lines for Log10(dose) are accepted as parallel ($\alpha=5\%$)

Equation of Probit Line
female : $\text{Probit} = -24.4 + 8.856 \cdot \text{Log10}(dose)$
male : $\text{Probit} = -23.8 + 8.856 \cdot \text{Log10}(dose)$




Female LD₅₀ = 2082 95% Range of Confidence (simultaneously): 1010 to 3050
Male LD₅₀ = 1794 95% Range of Confidence (simultaneously): 519.2 to 2418
Activity Ratio = 1.161 95% Range of Confidence: 0.785 to 2.196

Program : ED 1.1
Substance : 4-(2-Methoxyethyl)-phenol
Species : rat

Run Date : 04/08/93
Study No. : 93.0253
Administration : per os

Equation of Probit Line
female and male: Probit=-23.4+8.634*Log10(dose)





UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

Susan P. Engelman
Vice President
Environmental Health & Safety Affairs
Hoechst Celanese Corporation
Route 202-206
P.O. Box 2500
Somerville, New Jersey 08876-1258

OFFICE OF
PESTICIDES AND TOXIC
SUBSTANCES

JAN 18 1994

This letter formally acknowledges EPA's receipt of information submitted by your organization under Section 8(e), the "substantial risk" information reporting provision of the Toxic Substances Control Act (TSCA). For your reference, copies of the first page(s) of your submission(s) are enclosed and display the TSCA Section 8(e) Document Control Number (i.e., 8EHQ-0000-0000 Init.) assigned by EPA to your submission(s). Please refer to this cited number when submitting follow-up or supplemental information.

Please note that all submitted correspondence will be placed in the public files unless confidentiality is claimed according to the procedures outlined in Part X of EPA's TSCA Section 8(e) policy statement (43 FR 11110, March 16, 1978).

Confidential submissions submitted pursuant to the TSCA Section 8(e) Compliance Audit Program (CAP) should already contain information supporting confidentiality claims, because substantiation of CBI claims is required at the same time the 8(e) CAP is submitted to EPA. (If not done so already, please ensure that this information is provided to the Agency). When substantiating any/all claims, answer the questions detailed in the following attachment.

For NON-CAP submissions, any confidentiality claims should be supported by submission of information as described in the attachment(s).

12725 A

CERCAT/STRIAGE TRACKING DBASE. ENTRY FORM

CERCAT DATA:
Submission # 8E110

1093 - 12725

SEQ. A

TYPE: IN. SLIP FLWP

SUBMITTER NAME: Hoechst Elanese
Corporation

INFORMATION REQUESTED: FLWI DATE:

- 0501 NO INFO REQUESTED
 0502 INFO REQUESTED (TECH)
 0503 INFO REQUESTED (VOL ACTIONS)
 0504 INFO REQUESTED (REPORTING RATIONALE)

DISPOSITION:

- 0650 REFER TO CHEMICAL SCREENING
 0678 CAP NOTICE

VOLUNTARY ACTIONS:

- 0401 NO ACTION REPORTED
 0402 STUDIES PLANNED/UNDERWAY
 0403 NOTIFICATION OF WORKER/OTHERS
 0404 LABEL/MSDS CHANGES
 0405 PROCESS/HANDLING CHANGES
 0406 APP/USE DISCONTINUED
 0407 PRODUCTION DISCONTINUED
 0408 CONFIDENTIAL

SUB. DATE: 10/04/93

OTS DATE: 10/14/93

CSRAD DATE: 10/25/93

CASE#

5678-71-9

CHEMICAL NAME:
Phenol, 4-(2-methoxyethyl)-

INFORMATION TYPE:

P F C

INFORMATION TYPE:

P F C

INFORMATION TYPE:

P F C

0201	ONCO (HUMAN)	01 02 04
0202	ONCO (ANIMAL)	01 02 04
0203	CELL. TRANS (IN VITRO)	01 02 04
0204	MUTA (IN VITRO)	01 02 04
0205	MUTA (IN VIVO)	01 02 04
0206	REPRO/TERATO (HUMAN)	01 02 04
0207	REPRO/TERATO (ANIMAL)	01 02 04
0208	NEURO (HUMAN)	01 02 04
0209	NEURO (ANIMAL)	01 02 04
0210	ACUTE TOX. (HUMAN)	01 02 04
0211	CHR. TOX. (HUMAN)	01 02 04
0212	ACUTE TOX. (ANIMAL)	01 02 04
0213	SUB ACUTE TOX (ANIMAL)	01 02 04
0214	SUB CHRONIC TOX (ANIMAL)	01 02 04
0215	CHRONIC TOX (ANIMAL)	01 02 04

0216	EPICLIN
0217	HUMAN EXPOS (PROD CONTAM)
0218	HUMAN EXPOS (ACCIDENTAL)
0219	HUMAN EXPOS (MONITORING)
0220	ECO/AQUA TOX
0221	ENV. OCCURRENCE/FATE
0222	EMER INCI OF ENV CONTAM
0223	RESPONSE REQUEST DELAY
0224	PROD/COMP/CHEM ID
0225	REPORTING RATIONALE
0226	CONFIDENTIAL
0227	ALLERG (HUMAN)
0228	ALLERG (ANIMAL)
0229	METABPHARMA (ANIMAL)
0240	METABPHARMA (HUMAN)

0241	IMMUNO (ANIMAL)
0242	IMMUNO (HUM. N)
0243	CHEMPHYS PROP
0244	CLASTO (IN VITRO)
0245	CLASTO (ANIMAL)
0246	CLAS IO (HUMAN)
0247	DNA DAM/REPAIR
0248	PROD/USE/PROC
0251	MSDS
0259	OTHER

01 02 04
01 02 04
01 02 04
01 02 04
01 02 04
01 02 04
01 02 04
01 02 04
01 02 04
01 02 04
01 02 04
01 02 04
01 02 04
01 02 04

INJAC DATE: NON-CB. INVENTORY

ONGOING REVIEW

SPECIES

TOXICOLOGICAL CONCERN:

USE:

PRODUCTION:

YES (CONTINUE)

YES (DROP/REFER)

RAT

LOW

Acute oral toxicity

R&D

NO (DROP)

NO (CONTINUE)

MED

DETERMINE

REFER:

HIGH

COMMENTS: Non-Cap

Acute oral toxicity in the rat is low concern, based on a calculated oral acute LD₅₀ of 1933 mg/kg. combined
 Rats were dosed once. Doses + corresponding mortality were: 1000 mg/kg (0/10), 2000 mg/kg (6/10), and 2500 mg/kg (8/10). Clinical signs at all doses included: decreased spontaneous activity; still leg, uncoordinated or ataxic gait, stupor, narcosis, prone position.

At 2500 mg/kg 110 rats exhibited no pawreflex to pinching, and at ≥ 2000 mg/kg corneal reflex was absent. Possible toxicity to the liver, stomach + intestines.

CHEMNAME:	PHENOL, 4-(2-METHOXYETHYL)-		
CAS #:	COMPOSITION:		
ID:	8(e)-12725A	CBI	056718-71-9 CAP N
ASSESSMENTS/REGULATIONS:			
INFORMATION TYPE:	TEST SPECIES:	TOX CONCERN:	
ATOX/NEUR	RAT		
TRIAGE COMMENTS:			
OTHER SUMMARY:			
SUBMITTER USES:			
INITIAL DISPO DATE: R&D			
STANDARD REFERRALS +:	FOLLOWUP/ADDITIONAL INFO NEEDED		
CONTINUE ASSESSMENT: <i>N</i>	RATIONALE: <i>Low Toxicity</i>		
ADDITIONAL COMMENTS:			

CHEMNAME:	PHENOL, 4-(2-METHOXYETHYL)-		
CAS #:	8(e)-12725A		
ADDITIONAL USES:	056718-71-9	ID NUMBER:	
TRI RELEASES:			
ADDITIONAL TOXICITY:			
EXPOSURE/TOX SUMMARY:			
FINAL DISPO DATE:	SCREENER:	FINAL DISPO:	

OCCLUSURGE TRACKING DRUGS ENTRY FORM

VII. INJURY ACTIONS

IMAGE DATA 3-CHQ - 1293-12725 SUB B
 Submission #
 TYPE INT SUPP P.W.P
 SUBMITTER NAME Hoechst Celanese Corporation

INFORMATION REQUESTED: FLW/P DATE:
 0501 NO INFO REQUESTED
 0502 INFO REQUESTED (TECH)
 0503 INFO REQUESTED (VOL ACTIONS)
 0504 INFO REQUESTED (REPORTING RATIONALE)
 DISPOSITION:
 0639 REFER TO CHEMICAL SCREENING
 0678 CAP NOTICE

0401 NO ACTION REPORTED
 0402 STUDIES PLANNED UNDERWAY
 0403 NOTIFICATION OF WORKER OUTERS
 0404 LABEL/MSDS CHANGES
 0405 PROCESS/HANDLING CHANGES
 0406 APPAUSE DISCONTINUED
 0407 PRODUCTION DISCONTINUED
 0408 CONFIDENTIAL

SUB DATE 12/13/93 OIS DATE 12/21/93 CSB DATE 01/21/94
CASE#
56718-71-9

CHIMICAL NAME 1-hydroxy-4-(2-methoxyethyl)-

INFORMATION TYPE:
P_E_C
 0201 ONCO (HUMAN)
 0202 ONCO (ANIMAL)
 0203 CELL TRANS (IN VITRO)
 0204 MUTA (IN VITRO)
 0205 MUTA (IN VIVO)
 0206 REPROTERATO (HUMAN)
 0207 REPROTERATO (ANIMAL)
 0208 NEURO (HUMAN)
 0209 NEURO (ANIMAL)
 0210 ACUTE TOX. (HUMAN)
 0211 CIR. TOX. (HUMAN)
 0212 ACUTE TOX. (ANIMAL)
 0213 SUB ACUTE TOX (ANIMAL)
 0214 SUR CHRONIC TOX (ANIMAL)
 0215 CHRONIC TOX (ANIMAL)

INFORMATION TYPE:
P_E_C
 01 02 04 0216 EPICLIN
 01 02 04 0217 HUMAN EXPOS (PROD CONTAM)
 01 02 04 0218 HUMAN EXPOS (ACCIDENTAL)
 01 02 04 0219 HUMAN EXPOS (MONITORING)
 01 02 04 0220 ECOTOXAQIA TOX
 01 02 04 0221 ENV. OCCURELFATE
 01 02 04 0222 EMER. INCI OF ENV CONTAM
 01 02 04 0223 RESPONSE REQUEST DELAY
 01 02 04 0224 PRODCOMP/CHM ID
 01 02 04 0225 REPORTING RATIONALE
 01 02 04 0226 CONFIDENTIAL
 01 02 04 0227 ALLERG (HUMAN)
 01 02 04 0228 ALLERG (ANIMAL)
 01 02 04 0229 METABPHARMACO (ANIMAL)
 01 02 04 0230 METABPHARMACO (HUMAN)

INFORMATION TYPE:
P_E_C
 01 02 04 0241 IMMUNO (ANIMAL)
 01 02 04 0242 IMMUNO (HUMAN)
 01 02 04 0243 CHEMATHYS PROF
 01 02 04 0244 CLASTO (IN VITRO)
 01 02 04 0245 CLASTO (ANIMAL)
 01 02 04 0246 CLASTO (HUMAN)
 01 02 04 0247 DNA DAMIREPAIR
 01 02 04 0248 PRODMSE/PROC
 01 02 04 0251 MSDS
 01 02 04 0259 OTHER

USE:PRODUCTION:

IMAGE DATA NON-CBI INVENTORY ONGOING REVIEW RAT SPECIES RAT
 YES (CONTINUE) LOW TOXICOLOGICAL CONCERN
 NO (CONTINUE) LOW Acute Oral Toxicity

NO (DROP)
DETERMINE

REFER:

MED

HIGH

COMMENTS: Non-Cap Acute oral toxicity. Rats received oral doses of 1000, 2000, and 2500 mg/kg/day. Deaths (day 1) were as follows: 0/10 at 1000 mg/kg/day; 1/10 at 2000 mg/kg/day; and 9/10 at 2500 mg/kg/day. Trunked animals calculate oral LD₅₀ for males and females is 1933 (1225-2282) mg/kg/day. Signs observed showed impaired respiration and mobility, reduced reflexes, narcosis, and prone position. All signs cleared by day 8.

